{"id":"https://openalex.org/W4282936095","doi":"https://doi.org/10.1158/1538-7445.am2022-416","title":"Abstract 416: A novel non-covalent and rapidly reversible proteasome inhibitor for multiple myeloma and various solid cancers","display_name":"Abstract 416: A novel non-covalent and rapidly reversible proteasome inhibitor for multiple myeloma and various solid cancers","publication_year":2022,"publication_date":"2022-06-15","ids":{"openalex":"https://openalex.org/W4282936095","doi":"https://doi.org/10.1158/1538-7445.am2022-416"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2022-416","doi":"https://doi.org/10.1158/1538-7445.am2022-416","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2022-416","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Won-Gyun Ahn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158309","display_name":"Qurient (South Korea)","ror":"https://ror.org/058kbr222","country_code":"KR","type":"company","lineage":["https://openalex.org/I4210158309"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Won-Gyun Ahn","raw_affiliation_strings":["1Qurient Co.,Ltd., Seongnam-si, Republic of Korea;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Qurient Co.,Ltd., Seongnam-si, Republic of Korea;","institution_ids":["https://openalex.org/I4210158309"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066670477","display_name":"Yeejin Jeon","orcid":"https://orcid.org/0000-0002-8413-4406","observed_orcids":["https://orcid.org/0000-0002-8413-4406"]},"institutions":[{"id":"https://openalex.org/I4210158309","display_name":"Qurient (South Korea)","ror":"https://ror.org/058kbr222","country_code":"KR","type":"company","lineage":["https://openalex.org/I4210158309"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Yeejin Jeon","raw_affiliation_strings":["1Qurient Co.,Ltd., Seongnam-si, Republic of Korea;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Qurient Co.,Ltd., Seongnam-si, Republic of Korea;","institution_ids":["https://openalex.org/I4210158309"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069485567","display_name":"Yeong\u2010In Yang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158309","display_name":"Qurient (South Korea)","ror":"https://ror.org/058kbr222","country_code":"KR","type":"company","lineage":["https://openalex.org/I4210158309"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Yeong-In Yang","raw_affiliation_strings":["1Qurient Co.,Ltd., Seongnam-si, Republic of Korea;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Qurient Co.,Ltd., Seongnam-si, Republic of Korea;","institution_ids":["https://openalex.org/I4210158309"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101818961","display_name":"Jaeseung\u00a0C. Kim","orcid":"https://orcid.org/0009-0009-0387-8525","observed_orcids":["https://orcid.org/0009-0009-0387-8525"]},"institutions":[{"id":"https://openalex.org/I4210158309","display_name":"Qurient (South Korea)","ror":"https://ror.org/058kbr222","country_code":"KR","type":"company","lineage":["https://openalex.org/I4210158309"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Jaeseung Kim","raw_affiliation_strings":["1Qurient Co.,Ltd., Seongnam-si, Republic of Korea;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Qurient Co.,Ltd., Seongnam-si, Republic of Korea;","institution_ids":["https://openalex.org/I4210158309"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100621701","display_name":"Seungjoo Lee","orcid":"https://orcid.org/0000-0003-0641-3917","observed_orcids":["https://orcid.org/0000-0003-0641-3917"]},"institutions":[{"id":"https://openalex.org/I4210158309","display_name":"Qurient (South Korea)","ror":"https://ror.org/058kbr222","country_code":"KR","type":"company","lineage":["https://openalex.org/I4210158309"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Seung-Joo Lee","raw_affiliation_strings":["1Qurient Co.,Ltd., Seongnam-si, Republic of Korea;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Qurient Co.,Ltd., Seongnam-si, Republic of Korea;","institution_ids":["https://openalex.org/I4210158309"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Uwe Koch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128277","display_name":"Feuerwehr Dortmund","ror":"https://ror.org/02b7wb227","country_code":"DE","type":"government","lineage":["https://openalex.org/I4210128277"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Uwe Koch","raw_affiliation_strings":["2QLi5 Therapeutics GmbH, Dortmund, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2QLi5 Therapeutics GmbH, Dortmund, Germany;","institution_ids":["https://openalex.org/I4210128277"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037361420","display_name":"Gunther Zischinsky","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210120403","display_name":"Lead Discovery Center (Germany)","ror":"https://ror.org/02jy4mx12","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210120403"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Gunther Zischinsky","raw_affiliation_strings":["3Lead Discovery Center GmbH, Dortmund, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Lead Discovery Center GmbH, Dortmund, Germany;","institution_ids":["https://openalex.org/I4210120403"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090413812","display_name":"Axel Choidas","orcid":"https://orcid.org/0000-0003-2132-4939","observed_orcids":["https://orcid.org/0000-0003-2132-4939"]},"institutions":[{"id":"https://openalex.org/I4210120403","display_name":"Lead Discovery Center (Germany)","ror":"https://ror.org/02jy4mx12","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210120403"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Axel Choidas","raw_affiliation_strings":["3Lead Discovery Center GmbH, Dortmund, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Lead Discovery Center GmbH, Dortmund, Germany;","institution_ids":["https://openalex.org/I4210120403"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110760531","display_name":"Ayesha Pasha","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210120403","display_name":"Lead Discovery Center (Germany)","ror":"https://ror.org/02jy4mx12","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210120403"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Ayesha Pasha","raw_affiliation_strings":["3Lead Discovery Center GmbH, Dortmund, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Lead Discovery Center GmbH, Dortmund, Germany;","institution_ids":["https://openalex.org/I4210120403"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009093201","display_name":"Bert Klebl","orcid":"https://orcid.org/0000-0001-5475-9053","observed_orcids":["https://orcid.org/0000-0001-5475-9053"]},"institutions":[{"id":"https://openalex.org/I4210120403","display_name":"Lead Discovery Center (Germany)","ror":"https://ror.org/02jy4mx12","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210120403"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Bert Klebl","raw_affiliation_strings":["3Lead Discovery Center GmbH, Dortmund, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Lead Discovery Center GmbH, Dortmund, Germany;","institution_ids":["https://openalex.org/I4210120403"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101832860","display_name":"Robert Huber","orcid":"https://orcid.org/0000-0002-0133-5334","observed_orcids":["https://orcid.org/0000-0002-0133-5334"]},"institutions":[{"id":"https://openalex.org/I4210150093","display_name":"Max Planck Institute of Biochemistry","ror":"https://ror.org/04py35477","country_code":"DE","type":"facility","lineage":["https://openalex.org/I149899117","https://openalex.org/I4210150093"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Robert Huber","raw_affiliation_strings":["4Max Planck Institut f\u00fcr Biochemie, Martinsried, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Max Planck Institut f\u00fcr Biochemie, Martinsried, Germany","institution_ids":["https://openalex.org/I4210150093"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061161584","display_name":"Michael Hamacher","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128277","display_name":"Feuerwehr Dortmund","ror":"https://ror.org/02b7wb227","country_code":"DE","type":"government","lineage":["https://openalex.org/I4210128277"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Michael Hamacher","raw_affiliation_strings":["2QLi5 Therapeutics GmbH, Dortmund, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2QLi5 Therapeutics GmbH, Dortmund, Germany;","institution_ids":["https://openalex.org/I4210128277"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103507697","display_name":"Kiyean Nam","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210158309","display_name":"Qurient (South Korea)","ror":"https://ror.org/058kbr222","country_code":"KR","type":"company","lineage":["https://openalex.org/I4210158309"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Kiyean Nam","raw_affiliation_strings":["1Qurient Co.,Ltd., Seongnam-si, Republic of Korea;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Qurient Co.,Ltd., Seongnam-si, Republic of Korea;","institution_ids":["https://openalex.org/I4210158309"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"82","issue":"12_Supplement","first_page":"416","last_page":"416"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":0.98580002784729,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":0.98580002784729,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10620","display_name":"Protease and Inhibitor Mechanisms","score":0.005499999970197678,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.005400000140070915,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.9100000262260437},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9049999713897705},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.972000002861023},{"id":"https://openalex.org/keywords/non-covalent-inhibitors","display_name":"non-covalent inhibitors","score":0.9480000138282776},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.9240000247955322},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8889999985694885},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.8080000281333923},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.7260000109672546},{"id":"https://openalex.org/keywords/ixazomib","display_name":"ixazomib","score":0.9200000166893005},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.6830000281333923}],"concepts":[{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.8309648633003235},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.802802324295044},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.7439321279525757},{"id":"https://openalex.org/C180577832","wikidata":"https://www.wikidata.org/wiki/Q127920","display_name":"Covalent bond","level":2,"score":0.6386759281158447},{"id":"https://openalex.org/C27740335","wikidata":"https://www.wikidata.org/wiki/Q14878333","display_name":"Proteasome","level":2,"score":0.6342741250991821},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5592743158340454},{"id":"https://openalex.org/C2780108899","wikidata":"https://www.wikidata.org/wiki/Q15366934","display_name":"Carfilzomib","level":4,"score":0.5012602806091309},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4940245747566223},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.44351497292518616},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4310288727283478},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.35665977001190186},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.3192148804664612},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.20122167468070984},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2022-416","doi":"https://doi.org/10.1158/1538-7445.am2022-416","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2022-416","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2049013176","https://openalex.org/W3214088986","https://openalex.org/W2041251801","https://openalex.org/W2058275417","https://openalex.org/W2326776542","https://openalex.org/W4254421610","https://openalex.org/W2166753257","https://openalex.org/W2073311974","https://openalex.org/W2525044694","https://openalex.org/W3030289084"],"abstract_inverted_index":{"Abstract":[0],"The":[1],"existing":[2],"proteasome":[3,46,94,119,185,195,244],"inhibitors,":[4,111],"such":[5,81],"as":[6,82,96,104,106],"bortezomib":[7],"and":[8,28,38,56,84,91,149,168,192,204,241,249],"ixazomib,":[9],"are":[10,23,29,115,197],"effective":[11],"in":[12,59,64,131,173],"multiple":[13,107,132,202,247],"myeloma,":[14],"but":[15,51],"have":[16,48,71],"little":[17],"activity":[18],"against":[19,101],"solid":[20,65,102,177,208,251],"tumors.":[21,66,209],"These":[22,109,187],"covalent":[24,45],"boronic":[25],"acid-based":[26],"compounds":[27,159],"associated":[30],"with":[31],"undesired":[32],"side":[33],"effects,":[34],"mainly":[35],"hematologic":[36,137],"toxicity":[37,138],"peripheral":[39],"neuropathy.":[40],"A":[41,238],"variety":[42],"of":[43,53,145,156,176,256],"improved":[44,140,153],"inhibitors":[47,120,196],"been":[49],"developed,":[50],"lack":[52],"oral":[54],"availability":[55],"low":[57],"distribution":[58,163],"tumors":[60,103],"make":[61],"them":[62],"ineffective":[63],"In":[67],"addition,":[68],"they":[69],"still":[70],"a":[72,89,97],"narrow":[73],"therapeutic":[74],"window":[75],"due":[76],"to":[77,184],"unexpected":[78],"adverse":[79],"effects":[80],"cardiac":[83],"pulmonary":[85],"toxicity.":[86],"We":[87],"report":[88],"non-covalent":[90,116,191,240],"rapidly":[92,193,242],"reversible":[93,194,243],"inhibitor":[95,245],"potential":[98,205],"anti-cancer":[99],"agent":[100],"well":[105],"myeloma.":[108],"novel":[110,239],"called":[112],"QL":[113,158],"compounds,":[114],"chymotrypsin-like":[117],"selective":[118],"that":[121,181,190],"can":[122],"be":[123],"taken":[124],"orally.":[125],"They":[126],"effectively":[127],"inhibited":[128],"tumor":[129,170],"growth":[130,171],"myeloma":[133,203,248],"xenograft":[134,179],"model":[135],"without":[136],"through":[139],"PK":[141,154],"properties,":[142],"especially":[143],"partition":[144],"compound":[146],"between":[147],"plasma":[148],"RBC.":[150],"Moreover,":[151],"this":[152],"properties":[155],"the":[157,165,257],"allowed":[160],"for":[161,201,207,246,260],"sufficient":[162],"outside":[164],"blood":[166],"compartment":[167],"induced":[169],"inhibition":[172],"some":[174],"types":[175],"cancer":[178],"models":[180],"were":[182],"sensitive":[183],"inhibition.":[186],"results":[188],"indicate":[189],"an":[198],"ideal":[199],"strategy":[200],"agents":[206],"Citation":[210],"Format:":[211],"Won-Gyun":[212],"Ahn,":[213],"Yeejin":[214],"Jeon,":[215],"Yeong-In":[216],"Yang,":[217],"Jaeseung":[218],"Kim,":[219],"Seung-Joo":[220],"Lee,":[221],"Uwe":[222],"Koch,":[223],"Gunther":[224],"Zischinsky,":[225],"Axel":[226],"Choidas,":[227],"Ayesha":[228],"Pasha,":[229],"Bert":[230],"Klebl,":[231],"Robert":[232],"Huber,":[233],"Michael":[234],"Hamacher,":[235],"Kiyean":[236],"Nam.":[237],"various":[250],"cancers":[252],"[abstract].":[253],"In:":[254],"Proceedings":[255],"American":[258],"Association":[259],"Cancer":[261,272],"Research":[262],"Annual":[263],"Meeting":[264],"2022;":[265],"2022":[266],"Apr":[267],"8-13.":[268],"Philadelphia":[269],"(PA):":[270],"AACR;":[271],"Res":[273],"2022;82(12_Suppl):Abstract":[274],"nr":[275],"416.":[276]},"counts_by_year":[],"updated_date":"2026-10-13T10:08:12.033832","created_date":"2022-06-16T00:00:00"}